Skip to main content

Simplify Presents Six-figure Check to Susan G. Komen®, Marking One Year Since the Launch of the Simplify Health Care ETF (PINK)

PINK, the first pro bono ETF, is designed so all of Simplify’s net profits from managing the fund are donated on an annual basis to Komen, the world’s leading breast cancer organization

Simplify CEO Paul Kim and leadership team sponsored and participated in the Susan G. Komen OC MORE THAN PINK Walk in Newport Beach, CA, in September

Simplify Asset Management (“Simplify”), an innovative provider of Exchange Traded Funds (“ETFs”), is today presenting a check in the amount of $100,000 to Susan G. Komen®, the world’s leading breast cancer organization, to mark the one-year anniversary of the launch of the Simplify Health Care ETF (PINK), the first “pro bono” ETF.

This donation represents Simplify’s profits from one year of managing the PINK ETF, as this fund is designed so all such profits are donated to Susan G. Komen on an annual basis.

The presentation is taking place today at Simplify’s 2nd annual Entering the Fall Conference at the NYSE, a gathering of some of the leading minds in finance and investing focused on the latest investment outlook, product landscape and regulatory environment.

PINK is an actively managed fund overseen by renowned hedge fund investor Michael Taylor, who has more than 20 years of experience managing portfolios focused on the healthcare and biotech spaces, and who is highly regarded for his rigorous research approach, due diligence processes, and deep knowledge of these sectors.

"Our partnership with Simplify through the PINK Fund is an innovative example of the diverse ways organizations can support Susan G. Komen and meet donors where they are," said Paula Schneider, President and CEO of Komen. "Their support will benefit breast cancer patients across the nation as well as new discoveries and advancements for breast cancer treatment and financial support. Our mission is to create a world without breast cancer, and Simplify Asset Management is helping bring this mission to life."

“We are honored to be presenting our friends at Susan G. Komen with this donation,” said Paul Kim, CFA, CEO and Co-Founder with Simplify. “Much work is obviously still to be done in the ongoing battle against breast cancer, but we will continue to be unwavering in our support of Susan G. Komen and its incredibly important mission.”

MORE THAN PINK Walk

Simplify is a sponsor for the 2022 Komen OC MORE THAN PINK Walk and is participating with a Walk Team. Mr. Kim and Simplify joined Schneider and thousands of Orange County residents on Sept. 25, in Newport Beach to raise awareness and funds for breast cancer.

“We’re incredibly grateful for Simplify Asset Management for being a local sponsor of the Orange County MORE THAN PINK Walk and participating as a Walk Team. The Orange County MORE THAN PINK Walk raises funds to support Komen’s work in research and patient care services that are important to our community. The demand for our services is greater than ever and it is only through the support of our partners, like Simplify Asset Management, that we can provide support to the women and men facing breast cancer and metastatic breast cancer,” said Megan Klink, Regional Vice President of the West Region at Komen.

For more information on PINK and the Fund’s efforts to support Susan G. Komen, please visit https://www.simplify.us/etfs/pink-simplify-health-care-etf.

ABOUT SIMPLIFY ASSET MANAGEMENT INC.

Simplify Asset Management Inc. is a Registered Investment Adviser founded in 2020 to help advisors tackle the most pressing portfolio challenges with an innovative set of options-based strategies. By accounting for real-world investor needs and market behavior, along with the non-linear power of options, our strategies allow for the tailored portfolio outcomes for which clients are looking. For more information, visit www.simplify.us.

ABOUT SUSAN G. KOMEN

Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.

Investors should carefully consider the investment objectives, risks, charges and expenses of Exchange Traded Funds (ETFs) before investing. To obtain an ETF's prospectus containing this and other important information, please call (855) 772-8488, or visit SimplifyETFs.com. Please read the prospectus carefully before you invest. An investment in the fund involves risk, including possible loss of principal. Past performance does not guarantee future results.

The fund is new and has a limited operating history.

The Fund focuses its investments in securities of biotechnology and the healthcare industry. Economic, legislative or regulatory developments may occur that significantly affect these industries and cause the Fund’s net asset value to fluctuate due to this concentration.

The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits.

In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized have limited product lines, distribution channels, resources and more volatile than companies with greater capitalizations. Biotechnology companies must contend with high development costs, which may be exacerbated by the inability to raise prices to cover costs because of managed care pressure, government regulation or price controls. Companies in the pharmaceutical industry are heavily dependent on patent protection. The expiration of patents may adversely affect the profitability of the companies. Pharmaceutical companies are also subject to extensive litigation based liability and approval of the Food and Drug Administration, a process that can be long and costly. Expanding international operations may lead to risks resulting from differences between U.S. and foreign legal, political and economic systems, regulatory regimes and market practices.

The Fund’s focus on the healthcare sector may cause its value to fluctuate and be more susceptible to particular risks of the sector such as extensive government regulations, restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, an increased emphasis on outpatient services, changes in the demand for medical products and services, a limited number of products, industry innovation, changes in technologies and other market developments.

Simplify ETFs are distributed by Foreside Financial Services, LLC.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.